Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study

PPMI Sleep Working group on behalf of the PPMI Investigators

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objective: This study was undertaken to determine the frequency and correlates of excessive daytime sleepiness in de novo, untreated Parkinson's disease (PD) patients compared with the matched healthy controls. Methods: Data were obtained from the Parkinson's Progression Markers Initiative, an international study of de novo, untreated PD patients and healthy controls. At baseline, participants were assessed with a wide range of motor and nonmotor scales, including the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Excessive daytime sleepiness was assessed based on the Epworth Sleepiness scale (ESS), with a cutoff of 10. Results: Four hundred twenty-three PD subjects and 196 healthy controls were recruited into the study. Mean ESS (min, max) score was 5.8 (0, 20) for the PD subjects and 5.6 (0, 19) for healthy controls (P=0.54). Sixty-six (15.6%) PD subjects and 24 (12%) healthy controls had ESS of at least 10 (P=0.28). No difference was seen in demographic characteristics, age of onset, disease duration, PD subtype, cognitive status, or utilization of sedatives between the PD sleepiness-positive versus the negative group. The sleepiness-positive group had higher MDS-UPDRS Part I and II but not III scores, and higher depression and autonomic dysfunction scores. Sleepiness was associated with a marginal reduction of A-beta (P=0.05) but not alpha-synuclein spinal fluid levels in PD. Conclusions: This largest case control study demonstrates no difference in prevalence of excessive sleepiness in subjects with de novo untreated PD compared with healthy controls. The only clinical correlates of sleepiness were mood and autonomic dysfunction. Ongoing longitudinal analyses will be essential to further examine clinical and biological correlates of sleepiness in PD and specifically the role of dopaminergic therapy.

Original languageEnglish (US)
Pages (from-to)1371-1381
Number of pages11
JournalMovement Disorders
Volume30
Issue number10
DOIs
StatePublished - Sep 1 2015

Fingerprint

Parkinson Disease
Case-Control Studies
alpha-Synuclein
Movement Disorders
Hypnotics and Sedatives
Age of Onset
Healthy Volunteers
Demography
Depression

Keywords

  • Biomarkers
  • Daytime somnolence
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Correlates of excessive daytime sleepiness in de novo Parkinson's disease : A case control study. / PPMI Sleep Working group on behalf of the PPMI Investigators.

In: Movement Disorders, Vol. 30, No. 10, 01.09.2015, p. 1371-1381.

Research output: Contribution to journalArticle

PPMI Sleep Working group on behalf of the PPMI Investigators 2015, 'Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study', Movement Disorders, vol. 30, no. 10, pp. 1371-1381. https://doi.org/10.1002/mds.26248
PPMI Sleep Working group on behalf of the PPMI Investigators. / Correlates of excessive daytime sleepiness in de novo Parkinson's disease : A case control study. In: Movement Disorders. 2015 ; Vol. 30, No. 10. pp. 1371-1381.
@article{0461da3db59542ae91a61d7e1ad48ffb,
title = "Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study",
abstract = "Objective: This study was undertaken to determine the frequency and correlates of excessive daytime sleepiness in de novo, untreated Parkinson's disease (PD) patients compared with the matched healthy controls. Methods: Data were obtained from the Parkinson's Progression Markers Initiative, an international study of de novo, untreated PD patients and healthy controls. At baseline, participants were assessed with a wide range of motor and nonmotor scales, including the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Excessive daytime sleepiness was assessed based on the Epworth Sleepiness scale (ESS), with a cutoff of 10. Results: Four hundred twenty-three PD subjects and 196 healthy controls were recruited into the study. Mean ESS (min, max) score was 5.8 (0, 20) for the PD subjects and 5.6 (0, 19) for healthy controls (P=0.54). Sixty-six (15.6{\%}) PD subjects and 24 (12{\%}) healthy controls had ESS of at least 10 (P=0.28). No difference was seen in demographic characteristics, age of onset, disease duration, PD subtype, cognitive status, or utilization of sedatives between the PD sleepiness-positive versus the negative group. The sleepiness-positive group had higher MDS-UPDRS Part I and II but not III scores, and higher depression and autonomic dysfunction scores. Sleepiness was associated with a marginal reduction of A-beta (P=0.05) but not alpha-synuclein spinal fluid levels in PD. Conclusions: This largest case control study demonstrates no difference in prevalence of excessive sleepiness in subjects with de novo untreated PD compared with healthy controls. The only clinical correlates of sleepiness were mood and autonomic dysfunction. Ongoing longitudinal analyses will be essential to further examine clinical and biological correlates of sleepiness in PD and specifically the role of dopaminergic therapy.",
keywords = "Biomarkers, Daytime somnolence, Parkinson's disease",
author = "{PPMI Sleep Working group on behalf of the PPMI Investigators} and Tanya Simuni and Chelsea Caspell-Garcia and Christopher Coffey and Chahine, {Lama M.} and Shirley Lasch and Oertel, {Wolfgang H.} and Geert Mayer and Birgit H{\"o}gl and Ron Postuma and Aleksandar Videnovic and Amara, {Amy Willis} and Ken Marek and David Russell and Stewart Factor and Penelope Hogarth and David Standaert and Robert Hauser and Joseph Jankovic and Matthew Stern and Lama Chahine and James Leverenz and Samuel Frank and Irene Richard and Klaus Seppi and Holly Shill and Hubert Fernandez and Daniela Berg and Isabel Wurster and Douglas Galasko and Zoltan Mari and David Brooks and Nicola Pavese and Paolo Barone and Stuart Isaacson and Alberto Espay and Dominic Rowe and Melanie Brandabur and James Tetrud and Grace Liang and Alex Iranzo and Eduardo Tolosa and Laura Leary and Cheryl Riordan and Linda Rees and Alicia Portillo and Art Lenahan and Karen Williams and Stephanie Guthrie and Ashlee Rawlins and Boeve, {Bradley F}",
year = "2015",
month = "9",
day = "1",
doi = "10.1002/mds.26248",
language = "English (US)",
volume = "30",
pages = "1371--1381",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Correlates of excessive daytime sleepiness in de novo Parkinson's disease

T2 - A case control study

AU - PPMI Sleep Working group on behalf of the PPMI Investigators

AU - Simuni, Tanya

AU - Caspell-Garcia, Chelsea

AU - Coffey, Christopher

AU - Chahine, Lama M.

AU - Lasch, Shirley

AU - Oertel, Wolfgang H.

AU - Mayer, Geert

AU - Högl, Birgit

AU - Postuma, Ron

AU - Videnovic, Aleksandar

AU - Amara, Amy Willis

AU - Marek, Ken

AU - Russell, David

AU - Factor, Stewart

AU - Hogarth, Penelope

AU - Standaert, David

AU - Hauser, Robert

AU - Jankovic, Joseph

AU - Stern, Matthew

AU - Chahine, Lama

AU - Leverenz, James

AU - Frank, Samuel

AU - Richard, Irene

AU - Seppi, Klaus

AU - Shill, Holly

AU - Fernandez, Hubert

AU - Berg, Daniela

AU - Wurster, Isabel

AU - Galasko, Douglas

AU - Mari, Zoltan

AU - Brooks, David

AU - Pavese, Nicola

AU - Barone, Paolo

AU - Isaacson, Stuart

AU - Espay, Alberto

AU - Rowe, Dominic

AU - Brandabur, Melanie

AU - Tetrud, James

AU - Liang, Grace

AU - Iranzo, Alex

AU - Tolosa, Eduardo

AU - Leary, Laura

AU - Riordan, Cheryl

AU - Rees, Linda

AU - Portillo, Alicia

AU - Lenahan, Art

AU - Williams, Karen

AU - Guthrie, Stephanie

AU - Rawlins, Ashlee

AU - Boeve, Bradley F

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Objective: This study was undertaken to determine the frequency and correlates of excessive daytime sleepiness in de novo, untreated Parkinson's disease (PD) patients compared with the matched healthy controls. Methods: Data were obtained from the Parkinson's Progression Markers Initiative, an international study of de novo, untreated PD patients and healthy controls. At baseline, participants were assessed with a wide range of motor and nonmotor scales, including the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Excessive daytime sleepiness was assessed based on the Epworth Sleepiness scale (ESS), with a cutoff of 10. Results: Four hundred twenty-three PD subjects and 196 healthy controls were recruited into the study. Mean ESS (min, max) score was 5.8 (0, 20) for the PD subjects and 5.6 (0, 19) for healthy controls (P=0.54). Sixty-six (15.6%) PD subjects and 24 (12%) healthy controls had ESS of at least 10 (P=0.28). No difference was seen in demographic characteristics, age of onset, disease duration, PD subtype, cognitive status, or utilization of sedatives between the PD sleepiness-positive versus the negative group. The sleepiness-positive group had higher MDS-UPDRS Part I and II but not III scores, and higher depression and autonomic dysfunction scores. Sleepiness was associated with a marginal reduction of A-beta (P=0.05) but not alpha-synuclein spinal fluid levels in PD. Conclusions: This largest case control study demonstrates no difference in prevalence of excessive sleepiness in subjects with de novo untreated PD compared with healthy controls. The only clinical correlates of sleepiness were mood and autonomic dysfunction. Ongoing longitudinal analyses will be essential to further examine clinical and biological correlates of sleepiness in PD and specifically the role of dopaminergic therapy.

AB - Objective: This study was undertaken to determine the frequency and correlates of excessive daytime sleepiness in de novo, untreated Parkinson's disease (PD) patients compared with the matched healthy controls. Methods: Data were obtained from the Parkinson's Progression Markers Initiative, an international study of de novo, untreated PD patients and healthy controls. At baseline, participants were assessed with a wide range of motor and nonmotor scales, including the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Excessive daytime sleepiness was assessed based on the Epworth Sleepiness scale (ESS), with a cutoff of 10. Results: Four hundred twenty-three PD subjects and 196 healthy controls were recruited into the study. Mean ESS (min, max) score was 5.8 (0, 20) for the PD subjects and 5.6 (0, 19) for healthy controls (P=0.54). Sixty-six (15.6%) PD subjects and 24 (12%) healthy controls had ESS of at least 10 (P=0.28). No difference was seen in demographic characteristics, age of onset, disease duration, PD subtype, cognitive status, or utilization of sedatives between the PD sleepiness-positive versus the negative group. The sleepiness-positive group had higher MDS-UPDRS Part I and II but not III scores, and higher depression and autonomic dysfunction scores. Sleepiness was associated with a marginal reduction of A-beta (P=0.05) but not alpha-synuclein spinal fluid levels in PD. Conclusions: This largest case control study demonstrates no difference in prevalence of excessive sleepiness in subjects with de novo untreated PD compared with healthy controls. The only clinical correlates of sleepiness were mood and autonomic dysfunction. Ongoing longitudinal analyses will be essential to further examine clinical and biological correlates of sleepiness in PD and specifically the role of dopaminergic therapy.

KW - Biomarkers

KW - Daytime somnolence

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84941178621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941178621&partnerID=8YFLogxK

U2 - 10.1002/mds.26248

DO - 10.1002/mds.26248

M3 - Article

C2 - 26095202

AN - SCOPUS:84941178621

VL - 30

SP - 1371

EP - 1381

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 10

ER -